OKYO — OKYO Pharma Balance Sheet
0.000.00%
- $84.25m
- $82.15m
- 19
- 24
- 62
- 26
Annual balance sheet for OKYO Pharma, fiscal year end - March 31st, GBP millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | R2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 4.99 | 2.06 | 4.05 | 0.827 | 1.56 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.055 | 0.672 | 0.98 | 0.581 | 1.89 |
| Prepaid Expenses | |||||
| Total Current Assets | 5.06 | 3.27 | 5.2 | 1.54 | 3.68 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.076 | 0.004 | 0.007 | 0.003 | 0.002 |
| Total Assets | 5.14 | 3.27 | 5.2 | 1.54 | 3.68 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.24 | 1.03 | 7.26 | 7.42 | 9.23 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 1.28 | 1.03 | 7.26 | 7.42 | 9.23 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 3.85 | 2.24 | -2.05 | -5.88 | -5.55 |
| Total Liabilities & Shareholders' Equity | 5.14 | 3.27 | 5.2 | 1.54 | 3.68 |
| Total Common Shares Outstanding |